Neurocrine Biosciences Inc
(NAS:NBIX)
$
126.59
-1.32 (-1.03%)
Market Cap: 12.82 Bil
Enterprise Value: 11.84 Bil
PE Ratio: 33.94
PB Ratio: 4.71
GF Score: 85/100 Neurocrine Biosciences Inc at RBC Global Healthcare Conference (Virtual) Transcript
May 19, 2020 / 07:40PM GMT
Release Date Price:
$119.93
(-3.60%)
Brian Corey Abrahams
RBC Capital Markets, Research Division - Senior Biotechnology Analyst
Welcome everyone. I'm Brian Abrahams, one of the senior biotech analysts at RBC Capital Markets. We're very pleased to have our next featured company, Neurocrine, and their CEO, Kevin Gorman. Kevin, thanks so much for joining us.
Kevin C. Gorman
Neurocrine Biosciences, Inc. - CEO & Director
Hey, Brian, thank you very much for having me, and thank you to RBC for offering us this time.
Brian Corey Abrahams;Kevin C. Gorman
RBC Capital Markets, Research Division - Senior Biotechnology Analyst;
Our pleasure. So maybe just to kick things off and get started. I would love to hear just a quick several-minute update on the latest developments in Neurocrine and sort of where the company stands today coming out of the last earnings and given some of the developments on the commercial side for INGREZZA as well as the pipeline. And then would love to drill down more on some of those during the Q&A.
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot